Skip to main content

Expression Analysis Starts Providing Sequencing Services on PacBio RS

Premium

Genomics service provider Expression Analysis said this week that it has begun offering sequencing services on Pacific Biosciences' single-molecule sequencing platform.

The company, based in Durham, NC, said it is the first commercial provider offering services on the PacBio RS system in the US.

According to EA, first applications for the PacBio RS include de novo and hybrid genome assemblies, pathogen identification, and targeted resequencing. The company said it has already lined up several sequencing projects, including viral and bacterial sequencing studies with a large undisclosed pharmaceutical client and with academic institutions and plant and animal studies with government and commercial organizations.

PacBio is recommending EA as its North American service provider for the pharmaceutical market. "Given their deep expertise working with new and emerging genomic technologies and the world's leading pharmaceutical companies, EA is a natural fit to be our recommended commercial partner for providing sequencing services to the drug discovery and development market," said Pat Brooks, vice president of sales at PacBio, in a statement.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.